Versucht aus den Beispielen menschlicher Übersetzungen das Übersetzen zu lernen.
von: Maschinelle Übersetzung
Bessere Übersetzung vorschlagen
Qualität:
Von professionellen Übersetzern, Unternehmen, Websites und kostenlos verfügbaren Übersetzungsdatenbanken.
dob nije značajna kovarijabla u farmakokinetičkoj analizi populacije bolesnika s akromegalijom.
age is not a significant covariate in the population pharmacokinetic analysis of patients with acromegaly.
Letzte Aktualisierung: 2017-04-26
Nutzungshäufigkeit: 1
Qualität:
pokazalo se da je dob kovarijabla u farmakokinetičkoj analizi populacije bolesnika s cushingovom bolešću.
age has been found to be a covariate in the population pharmacokinetic analysis of cushing’s disease patients.
Letzte Aktualisierung: 2017-04-26
Nutzungshäufigkeit: 1
Qualität:
otkriveno je da je tjelesna težina kovarijabla u farmakokinetičkoj analizi populacije bolesnika s cushingovom bolešću.
body weight has been found to be a covariate in the population pharmacokinetic analysis of cushing’s disease patients.
Letzte Aktualisierung: 2017-04-26
Nutzungshäufigkeit: 1
Qualität:
u farmakokinetičkoj analizi populacije, nije bilo indikacija o učinku duhana ili alkohola na farmakokinetiku ustekinumaba.
in the population pharmacokinetic analysis, there were no indications of an effect of tobacco or alcohol on the pharmacokinetics of ustekinumab.
Letzte Aktualisierung: 2017-04-26
Nutzungshäufigkeit: 1
Qualität:
prema populacijskoj farmakokinetičkoj analizi koja je uključivala 210 žena i 277 muškaraca, spol ne utječe na izloženost kobimetinibu.
gender does not have an effect on the exposure of cobimetinib, based on a population pharmacokinetic analysis including 210 women and 277 men.
Letzte Aktualisierung: 2017-04-26
Nutzungshäufigkeit: 1
Qualität:
osim toga, u populacijskoj farmakokinetičkoj analizi nije bilo znakova interakcije između pertuzumaba i trastuzumaba ni između pertuzumaba i docetaksela.
in addition, in the population pk analysis, no evidence of a drug-drug interaction has been shown between pertuzumab and trastuzumab or between pertuzumab and docetaxel.
Letzte Aktualisierung: 2017-04-26
Nutzungshäufigkeit: 1
Qualität:
prema populacijskoj farmakokinetičkoj analizi, apsolutna bioraspoloživost alirokumaba nakon supkutane primjene iznosila je približno 85%.
the absolute bioavailability of alirocumab after subcutaneous administration was about 85% as determined by population pharmacokinetic analysis.
Letzte Aktualisierung: 2017-04-26
Nutzungshäufigkeit: 1
Qualität:
linearni klirens mjerio se kao parametar u populacijskoj farmakokinetičkoj analizi i iznosio je 0,142 ml/h/kg.
the linear clearance estimated as a parameter in the population pharmacokinetic analysis, was 0.142 ml/hr/kg.
Letzte Aktualisierung: 2017-04-26
Nutzungshäufigkeit: 1
Qualität:
farmakokinetika intravenski primijenjenog mepolizumaba ocijenjena je u populacijskoj farmakokinetičkoj analizi u pedijatrijskom ispitivanju provedenom s ispitanicima u dobi od 2 do 17 godina s eozinofilnim ezofagitisom.
intravenous mepolizumab pharmacokinetics was evaluated by population pharmacokinetic analysis in a paediatric study conducted in subjects aged 2–17 years old with eosinophilic esophagitis.
Letzte Aktualisierung: 2017-04-26
Nutzungshäufigkeit: 1
Qualität:
u populacijskoj farmakokinetičkoj analizi bolesnika s tuberkulozom liječenih lijekom sirturo, otkriveno je da je izloženost bedakilinu niža u bolesnika crne rase nego u bolesnika koji pripadaju drugim rasama.
in a population pharmacokinetic analysis of tuberculosis patients treated with sirturo, exposure to bedaquiline was found to be lower in black patients than in patients from other race categories.
Letzte Aktualisierung: 2017-04-26
Nutzungshäufigkeit: 1
Qualität:
ne postoje razlike u farmakokinetici aripiprazola između zdravih ispitanika muškog i ženskog spola, niti postoji ikakav prepoznatljiv učinak spola u populacijskoj farmakokinetičkoj analizi u bolesnika sa shizofrenijom.
there are no differences in the pharmacokinetics of aripiprazole between healthy male and female subjects nor is there any detectable effect of gender in a population pharmacokinetic analysis in schizophrenic patients.
Letzte Aktualisierung: 2017-04-26
Nutzungshäufigkeit: 1
Qualität:
ove karakteristike nisu imale klinički značajan učinak na farmakokinetiku simeprevira temeljeno na populacijskoj farmakokinetičkoj analizi hcv-om inficiranih bolesnika liječenih simeprevirom u kombinaciji s peginterferonom alfa i ribavirinom.
these characteristics have no clinically relevant effect on the pharmacokinetics of simeprevir based on a population pharmacokinetic analysis of hcv infected patients treated with simeprevir in combination with peginterferon alfa and ribavirin.
Letzte Aktualisierung: 2017-04-26
Nutzungshäufigkeit: 1
Qualität:
prema populacijskoj farmakokinetičkoj analizi, medijan prividnog poluvijeka alirokumaba u stanju dinamičke ravnoteže iznosio je 17 do 20 dana u bolesnika koji su primali monoterapiju alirokumabom u supkutanim dozama od 75 mg jednom svaka 2 tjedna ili 150 mg jednom svaka 2 tjedna.
based on a population pharmacokinetic analysis, the median apparent half-life of alirocumab at steady state was 17 to 20 days in patients receiving alirocumab as monotherapy at subcutaneous doses of either 75 mg q2w or 150 mg q2w.
Letzte Aktualisierung: 2017-04-26
Nutzungshäufigkeit: 1
Qualität:
tjelesna težina je bila značajna kovarijanta u populacijskoj farmakokinetičkoj analizi, s utjecajem na najniže koncentracije evolokumaba, međutim bez utjecaja na smanjenje ldl-c-a.
body weight was a significant covariate in population pk analysis impacting evolocumab trough concentrations, however there was no impact on ldl-c reduction.
Letzte Aktualisierung: 2017-04-26
Nutzungshäufigkeit: 1
Qualität:
preporučene doze u djece i adolescenata temelje se na populacijskoj farmakokinetičkoj analizi podataka prikupljenih u 112 imunokompromitiranih pedijatrijskih bolesnika u dobi od 2 do < 12 godina i 26 imunokompromitiranih adolescentnih bolesnika u dobi 12 do < 17 godina.
the recommended doses in children and adolescent patients are based on a population pharmacokinetic analysis of data obtained from 112 immunocompromised paediatric patients aged 2 to <12 years and 26 immunocompromised adolescent patients aged 12 to <17 years.
Letzte Aktualisierung: 2017-04-26
Nutzungshäufigkeit: 1
Qualität:
Warnung: Enthält unsichtbare HTML-Formatierung
nisu pronađeni dokazi o farmakokinetičkoj ili farmakodinamičkoj interakciji s lijekovima koji se mogu propisati za istovremenu primjenu s lijekom thymanax u ciljanoj populaciji tijekom faze i kliničkih studija: benzodiazepini, litij, paroksetin, flukonazol i teofilin.
no evidence of pharmacokinetic or pharmacodynamic interaction with medicinal products which could be prescribed concomitantly with thymanax in the target population was found in phase i clinical trials: benzodiazepines, lithium, paroxetine, fluconazole and theophylline.
Letzte Aktualisierung: 2017-04-26
Nutzungshäufigkeit: 1
Qualität:
budući da su ispitanici koji nisu bijele rase činili < 3% ukupne populacije (6 crnaca, 219 bijelaca), rasa nije procjenjivana kao kovarijanta u populacijskoj farmakokinetičkoj analizi.
since the number of subjects who were not caucasian comprised only < 3% of the total population (6 black, 219 caucasian), race was not evaluated as a covariate in the population pharmacokinetic analysis.
Letzte Aktualisierung: 2017-04-26
Nutzungshäufigkeit: 1
Qualität:
Warnung: Enthält unsichtbare HTML-Formatierung